C4 Therapeutics is a clinical-stage company developing cemsidomide, an oral drug that degrades the IKZF1/3 proteins, for multiple myeloma; it is not approved.
C4's case rests on cemsidomide, an investigational oral IKZF1/3 degrader for multiple myeloma. Phase 1 with dexamethasone produced 40% and 53% response rates at the highest doses. MOMENTUM's initial response data are expected in the second half of 2027, supporting a potential accelerated-approval NDA by year-end 2028. Management expects funding through the end of 2028. Earlier-line combinations offer expansion potential; the discovery platform adds longer-term opportunities, with VAV1 dependent on a partner.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: MOMENTUM confirms the Phase 1 response rate
Does cemsidomide with dexamethasone deliver convincing responses and tolerability in MOMENTUM's late-line population?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Cemsidomide remains central as discovery platform adds partner-dependent opportunities
Cemsidomide's 53% Phase 1 ORR sets up MOMENTUM Phase 2 as the binary test for accelerated approval in late-line myeloma
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Blood cancers, Lung cancer, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
6 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.